LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 19

Search options

  1. Article ; Online: In Silico Identification and Evaluation of Natural Products as Potential Tumor Necrosis Factor Function Inhibitors Using Advanced Enalos Asclepios KNIME Nodes.

    Papadopoulou, Dimitra / Drakopoulos, Antonios / Lagarias, Panagiotis / Melagraki, Georgia / Kollias, George / Afantitis, Antreas

    International journal of molecular sciences

    2021  Volume 22, Issue 19

    Abstract: Tumor necrosis factor (TNF) is a regulator of several chronic inflammatory diseases, such as rheumatoid arthritis. Although anti-TNF biologics have been used in clinic, they render several drawbacks, such as patients' progressive immunodeficiency and ... ...

    Abstract Tumor necrosis factor (TNF) is a regulator of several chronic inflammatory diseases, such as rheumatoid arthritis. Although anti-TNF biologics have been used in clinic, they render several drawbacks, such as patients' progressive immunodeficiency and loss of response, high cost, and intravenous administration. In order to find new potential anti-TNF small molecule inhibitors, we employed an in silico approach, aiming to find natural products, analogs of Ampelopsin H, a compound that blocks the formation of TNF active trimer. Two out of nine commercially available compounds tested, Nepalensinol B and Miyabenol A, efficiently reduced TNF-induced cytotoxicity in L929 cells and production of chemokines in mice joints' synovial fibroblasts, while Nepalensinol B also abolished TNF-TNFR1 binding in non-toxic concentrations. The binding mode of the compounds was further investigated by molecular dynamics and free energy calculation studies, using and advancing the Enalos Asclepios pipeline. Conclusively, we propose that Nepalensinol B, characterized by the lowest free energy of binding and by a higher number of hydrogen bonds with TNF, qualifies as a potential lead compound for TNF inhibitors' drug development. Finally, the upgraded Enalos Asclepios pipeline can be used for improved identification of new therapeutics against TNF-mediated chronic inflammatory diseases, providing state-of-the-art insight on their binding mode.
    MeSH term(s) Animals ; Anti-Inflammatory Agents/chemistry ; Anti-Inflammatory Agents/pharmacology ; Binding Sites/drug effects ; Biological Products/chemistry ; Biological Products/pharmacology ; Cell Line ; Cell Survival/drug effects ; Computer Simulation ; Drug Design ; Drug Discovery/methods ; Fibroblasts/drug effects ; Mice ; Primary Cell Culture ; Synovial Fluid/drug effects ; Tumor Necrosis Factor Inhibitors/chemistry ; Tumor Necrosis Factor Inhibitors/pharmacology ; Tumor Necrosis Factor-alpha/toxicity
    Chemical Substances Anti-Inflammatory Agents ; Biological Products ; Tumor Necrosis Factor Inhibitors ; Tumor Necrosis Factor-alpha
    Language English
    Publishing date 2021-09-23
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2019364-6
    ISSN 1422-0067 ; 1422-0067 ; 1661-6596
    ISSN (online) 1422-0067
    ISSN 1422-0067 ; 1661-6596
    DOI 10.3390/ijms221910220
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Correction to Insights to the Binding of a Selective Adenosine A

    Lagarias, Panagiotis / Barkan, Kerry / Tzortzini, Eva / Stampelou, Margarita / Vrontaki, Eleni / Ladds, Graham / Kolocouris, Antonios

    Journal of chemical information and modeling

    2020  Volume 60, Issue 4, Page(s) 2405–2406

    Language English
    Publishing date 2020-03-25
    Publishing country United States
    Document type Published Erratum
    ZDB-ID 190019-5
    ISSN 1549-960X ; 0095-2338
    ISSN (online) 1549-960X
    ISSN 0095-2338
    DOI 10.1021/acs.jcim.0c00240
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: "Hit" to lead optimization and chemoinformatic studies for a new series of Autotaxin inhibitors.

    Stylianaki, Elli-Anna / Magkrioti, Christiana / Ladopoulou, Eleni M / Papavasileiou, Konstantinos D / Lagarias, Panagiotis / Melagraki, Georgia / Samiotaki, Martina / Panayotou, George / Dedos, Skarlatos G / Afantitis, Antreas / Aidinis, Vassilis / Matralis, Alexios N

    European journal of medicinal chemistry

    2023  Volume 249, Page(s) 115130

    Abstract: Robust experimental evidence has highlighted the role of Autotaxin (ATX)/Lysophosphatidic acid (LPA) axis not only in the pathogenesis of chronic inflammatory conditions and especially in fibroproliferative diseases but also in several types of cancer. ... ...

    Abstract Robust experimental evidence has highlighted the role of Autotaxin (ATX)/Lysophosphatidic acid (LPA) axis not only in the pathogenesis of chronic inflammatory conditions and especially in fibroproliferative diseases but also in several types of cancer. As a result, different series of substrate-, lipid-based and small-molecule ATX inhibitors have been identified thus far by both academia and pharma. The "crowning achievement" of these drug discovery campaigns was the development and entry of the first-in-class ATX inhibitor (ziritaxestat, GLPG-1690) in advanced clinical trials against idiopathic pulmonary fibrosis. Herein, the potency optimization efforts of a new series of Autotaxin inhibitors, namely 2-substituted-2,6-dihydro-4H-thieno[3,4-c]pyrazol-1-substituted amide, is described using a previously identified novel chemical scaffold as a "hit". The mode of inhibition of the most promising ATX inhibitors was investigated, while their cellular activity, aqueous solubility and cytotoxicity were evaluated. Our pharmacological results were corroborated by chemoinformatic tools (molecular docking and molecular dynamics simulations) deployed, to provide insight into the binding mechanism of the synthesized inhibitors to ATX.
    MeSH term(s) Humans ; Cheminformatics ; Chronic Disease ; Idiopathic Pulmonary Fibrosis/drug therapy ; Molecular Docking Simulation ; Neoplasms/drug therapy ; Phosphoric Diester Hydrolases/metabolism
    Chemical Substances Phosphoric Diester Hydrolases (EC 3.1.4.-) ; GLPG1690
    Language English
    Publishing date 2023-01-23
    Publishing country France
    Document type Journal Article
    ZDB-ID 188597-2
    ISSN 1768-3254 ; 0009-4374 ; 0223-5234
    ISSN (online) 1768-3254
    ISSN 0009-4374 ; 0223-5234
    DOI 10.1016/j.ejmech.2023.115130
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Insights to the Binding of a Selective Adenosine A

    Lagarias, Panagiotis / Barkan, Kerry / Tzortzini, Eva / Stampelou, Margarita / Vrontaki, Eleni / Ladds, Graham / Kolocouris, Antonios

    Journal of chemical information and modeling

    2019  Volume 59, Issue 12, Page(s) 5183–5197

    Abstract: Adenosine ... ...

    Abstract Adenosine A
    MeSH term(s) Adenosine A3 Receptor Antagonists/chemistry ; Adenosine A3 Receptor Antagonists/metabolism ; Adenosine A3 Receptor Antagonists/pharmacology ; Amides/chemistry ; Amides/metabolism ; Amides/pharmacology ; Melphalan/metabolism ; Melphalan/pharmacology ; Molecular Docking Simulation ; Molecular Dynamics Simulation ; Mutagenesis ; Poisson Distribution ; Protein Binding ; Protein Conformation ; Receptor, Adenosine A3/chemistry ; Receptor, Adenosine A3/genetics ; Receptor, Adenosine A3/metabolism ; Substrate Specificity ; Thermodynamics ; gamma-Globulins/metabolism ; gamma-Globulins/pharmacology
    Chemical Substances Adenosine A3 Receptor Antagonists ; Amides ; K-18 conjugate ; Receptor, Adenosine A3 ; gamma-Globulins ; Melphalan (Q41OR9510P)
    Language English
    Publishing date 2019-12-03
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 190019-5
    ISSN 1549-960X ; 0095-2338
    ISSN (online) 1549-960X
    ISSN 0095-2338
    DOI 10.1021/acs.jcim.9b00751
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: The L46P mutant confers a novel allosteric mechanism of resistance toward the influenza A virus M2 S31N proton channel blockers.

    Musharrafieh, Rami / Lagarias, Panagiotis I / Ma, Chunlong / Tan, Gene S / Kolocouris, Antonios / Wang, Jun

    Molecular pharmacology

    2019  Volume 96, Issue 2, Page(s) 148–157

    Abstract: The Food and Drug Administration-approved influenza A antiviral amantadine inhibits the wild-type (WT) AM2 channel but not the S31N mutant predominantly found in circulating strains. In this study, serial viral passages were applied to select resistance ... ...

    Abstract The Food and Drug Administration-approved influenza A antiviral amantadine inhibits the wild-type (WT) AM2 channel but not the S31N mutant predominantly found in circulating strains. In this study, serial viral passages were applied to select resistance against a newly developed isoxazole-conjugated adamantane inhibitor that targets the AM2 S31N channel. This led to the identification of the novel drug-resistant mutation L46P located outside the drug-binding site, which suggests an allosteric resistance mechanism. Intriguingly, when the L46P mutant was introduced to AM2 WT, the channel remained sensitive toward amantadine inhibition. To elucidate the molecular mechanism, molecular dynamics simulations and binding free energy molecular mechanics-generalized born surface area (MM-GBSA) calculations were performed on WT and mutant channels. It was found that the L46P mutation caused a conformational change in the N terminus of transmembrane residues 22-31 that ultimately broadened the drug-binding site of AM2 S31N inhibitor
    MeSH term(s) Allosteric Regulation/drug effects ; Amantadine/pharmacology ; Amino Acid Motifs ; Animals ; Antiviral Agents/chemistry ; Antiviral Agents/pharmacology ; Binding Sites ; Dogs ; Drug Resistance, Viral ; Female ; Humans ; Influenza A virus/drug effects ; Influenza A virus/metabolism ; Madin Darby Canine Kidney Cells ; Models, Molecular ; Molecular Dynamics Simulation ; Mutation ; Protein Conformation ; Serial Passage ; Structure-Activity Relationship ; Viral Matrix Proteins/chemistry ; Viral Matrix Proteins/genetics ; Xenopus laevis
    Chemical Substances Antiviral Agents ; M2 protein, Influenza A virus ; Viral Matrix Proteins ; Amantadine (BF4C9Z1J53)
    Language English
    Publishing date 2019-06-07
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
    ZDB-ID 124034-1
    ISSN 1521-0111 ; 0026-895X
    ISSN (online) 1521-0111
    ISSN 0026-895X
    DOI 10.1124/mol.119.116640
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Structural Characterization of Agonist Binding to an A

    Stamatis, Dimitrios / Lagarias, Panagiotis / Barkan, Kerry / Vrontaki, Eleni / Ladds, Graham / Kolocouris, Antonios

    Journal of medicinal chemistry

    2019  Volume 62, Issue 19, Page(s) 8831–8846

    Abstract: The adenosine ... ...

    Abstract The adenosine A
    MeSH term(s) Adenosine/analogs & derivatives ; Adenosine/chemistry ; Adenosine/metabolism ; Adenosine/pharmacology ; Adenosine A3 Receptor Agonists/chemistry ; Adenosine A3 Receptor Agonists/metabolism ; Adenosine A3 Receptor Agonists/pharmacology ; Animals ; Binding Sites ; CHO Cells ; Cricetinae ; Cricetulus ; Humans ; Hydrogen Bonding ; Molecular Dynamics Simulation ; Mutagenesis, Site-Directed ; Receptor, Adenosine A3/chemistry ; Receptor, Adenosine A3/genetics ; Receptor, Adenosine A3/metabolism ; Signal Transduction/drug effects ; Thermodynamics
    Chemical Substances Adenosine A3 Receptor Agonists ; Receptor, Adenosine A3 ; N(6)-(3-iodobenzyl)-5'-N-methylcarboxamidoadenosine (152918-18-8) ; Adenosine (K72T3FS567)
    Language English
    Publishing date 2019-09-27
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 218133-2
    ISSN 1520-4804 ; 0022-2623
    ISSN (online) 1520-4804
    ISSN 0022-2623
    DOI 10.1021/acs.jmedchem.9b01164
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Ebselen, Disulfiram, Carmofur, PX-12, Tideglusib, and Shikonin Are Nonspecific Promiscuous SARS-CoV-2 Main Protease Inhibitors.

    Ma, Chunlong / Hu, Yanmei / Townsend, Julia Alma / Lagarias, Panagiotis I / Marty, Michael Thomas / Kolocouris, Antonios / Wang, Jun

    ACS pharmacology & translational science

    2020  Volume 3, Issue 6, Page(s) 1265–1277

    Abstract: Among the drug targets being investigated for SARS-CoV-2, the viral main protease ( ... ...

    Abstract Among the drug targets being investigated for SARS-CoV-2, the viral main protease (M
    Language English
    Publishing date 2020-10-09
    Publishing country United States
    Document type Journal Article
    ISSN 2575-9108
    ISSN (online) 2575-9108
    DOI 10.1021/acsptsci.0c00130
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Investigation of the Drug Resistance Mechanism of M2-S31N Channel Blockers through Biomolecular Simulations and Viral Passage Experiments.

    Musharrafieh, Rami / Lagarias, Panagiotis / Ma, Chunlong / Hau, Raymond / Romano, Alex / Lambrinidis, George / Kolocouris, Antonios / Wang, Jun

    ACS pharmacology & translational science

    2020  Volume 3, Issue 4, Page(s) 666–675

    Abstract: Recent efforts in drug development against influenza A virus (IAV) M2 proton channel S31N mutant resulted in conjugates of amantadine linked with aryl head heterocycles. To understand the mechanism of drug resistance, we chose a representative M2-S31N ... ...

    Abstract Recent efforts in drug development against influenza A virus (IAV) M2 proton channel S31N mutant resulted in conjugates of amantadine linked with aryl head heterocycles. To understand the mechanism of drug resistance, we chose a representative M2-S31N inhibitor, compound
    Language English
    Publishing date 2020-03-31
    Publishing country United States
    Document type Journal Article
    ISSN 2575-9108
    ISSN (online) 2575-9108
    DOI 10.1021/acsptsci.0c00018
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article: Ebselen, disulfiram, carmofur, PX-12, tideglusib, and shikonin are non-specific promiscuous SARS-CoV-2 main protease inhibitors.

    Ma, Chunlong / Hu, Yanmei / Townsend, Julia Alma / Lagarias, Panagiotis I / Marty, Michael Thomas / Kolocouris, Antonios / Wang, Jun

    bioRxiv : the preprint server for biology

    2020  

    Abstract: There is an urgent need for vaccines and antiviral drugs to combat the COVID-19 pandemic. Encouraging progress has been made in developing antivirals targeting SARS-CoV-2, the etiological agent of COVID-19. Among the drug targets being investigated, the ... ...

    Abstract There is an urgent need for vaccines and antiviral drugs to combat the COVID-19 pandemic. Encouraging progress has been made in developing antivirals targeting SARS-CoV-2, the etiological agent of COVID-19. Among the drug targets being investigated, the viral main protease (M
    Keywords covid19
    Language English
    Publishing date 2020-09-16
    Publishing country United States
    Document type Preprint
    DOI 10.1101/2020.09.15.299164
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Ebselen, disulfiram, carmofur, PX-12, tideglusib, and shikonin are non-specific promiscuous SARS-CoV-2 main protease inhibitors

    Ma, Chunlong / Hu, Yanmei / Townsend, Julia Alma / Lagarias, Panagiotis / Marty, Michael Thomas / Kolocouris, Antonios / Wang, Jun

    bioRxiv

    Abstract: There is an urgent need for vaccines and antiviral drugs to combat the COVID-19 pandemic. Encouraging progress has been made in developing antivirals targeting SARS-CoV-2, the etiological agent of COVID-19. Among the drug targets being investigated, the ... ...

    Abstract There is an urgent need for vaccines and antiviral drugs to combat the COVID-19 pandemic. Encouraging progress has been made in developing antivirals targeting SARS-CoV-2, the etiological agent of COVID-19. Among the drug targets being investigated, the viral main protease (Mpro) is one of the most extensively studied drug targets. Mpro is a cysteine protease that hydrolyzes the viral polyprotein at more than 11 sites and it is highly conserved among coronaviruses. In addition, Mpro has a unique substrate preference for glutamine in the P1 position. Taken together, it appears that Mpro inhibitors can achieve both broad-spectrum antiviral activity and a high selectivity index. Structurally diverse compounds have been reported as Mpro inhibitors, with several of which also showed antiviral activity in cell culture. In this study, we investigated the mechanism of action of six previously reported Mpro inhibitors, ebselen, disulfiram, tideglusib, carmofur, shikonin, and PX-12 using a consortium of techniques including FRET-based enzymatic assay, thermal shift assay, native mass spectrometry, cellular antiviral assays, and molecular dynamics simulations. Collectively, the results showed that the inhibition of Mpro by these six compounds is non-specific and the inhibition is abolished or greatly reduced with the addition of reducing reagent DTT. In the absence of DTT, these six compounds not only inhibit Mpro, but also a panel of viral cysteine proteases including SARS-CoV-2 papain-like protease, the 2Apro and 3Cpro from enterovirus A71 (EV-A71) and EV-D68. However, none of the compounds inhibits the viral replication of EV-A71 or EV-D68, suggesting that the enzymatic inhibition potency IC50 values obtained in the absence of DTT cannot be used to faithfully predict their cellular antiviral activity. Overall, we provide compelling evidence suggesting that ebselen, disulfiram, tideglusib, carmofur, shikonin, and PX-12 are non-specific SARS-CoV-2 Mpro inhibitors, and urge the scientific community to be stringent with hit validation.
    Keywords covid19
    Language English
    Publishing date 2020-09-16
    Publisher Cold Spring Harbor Laboratory
    Document type Article ; Online
    DOI 10.1101/2020.09.15.299164
    Database COVID19

    Kategorien

To top